Atlas Trials

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Clinical trial NCT02433795 · COMPLETED

Trial details

NCT number
NCT02433795
Sponsor
Seoul National University Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Marginal Zone B-cell Lymphoma
Start date
2015-05-01
Primary completion
2019-10-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.